DDInter1956 DDInter342
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trastuzumab emtansine
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Zalcitabine {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Zalcitabine {u} (Compound) resembles {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Benznidazole
Benznidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Zalcitabine {u} (Compound) upregulates {v} (Gene) PAK6
PAK6 {u} (Gene) is upregulated by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Zalcitabine {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) is downregulated by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Zalcitabine {u} (Compound) causes {v} (Side Effect) Gastrointestinal pain
Gastrointestinal pain {u} (Side Effect) is caused by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may lead to a major life threatening interaction when taken with Certolizumab pegol
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Zalcitabine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Zalcitabine (Compound) resembles Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Zalcitabine (Compound) upregulates PAK6 (Gene) and PAK6 (Gene) is upregulated by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Zalcitabine (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Zalcitabine (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol